Patents by Inventor Takefumi Gemba
Takefumi Gemba has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10322173Abstract: Problem To provide a chiral nucleic acid adjuvant and anti-allergic agent having anti-allergic effect. Solution An adjuvant which comprises oligonucleotides which comprise two to four CpG motifs each represented by 5?-X1CpGX2-3? and has a length of 14 to 32 nucleotides, wherein a nucleic acid at 3? end side of at least two CpG motifs is connected by phosphorothioate linkage, wherein each nucleic acids at 3? end and 5? end of the oligonucleotide is S type nucleic acids connected by phosphorothioate linkage, and wherein the oligonucleotide comprises at least one nucleic acid without phosphorothioate modification. The present invention relates to an adjuvant comprising the oligonucleotide represented by the sequence number 67. The present invention relates to an anti-allergic agent comprising these adjuvant.Type: GrantFiled: January 14, 2015Date of Patent: June 18, 2019Assignees: SHIN NIPPON BIOMEDICAL LABORATORIES, LTD., WAVE LIFE SCIENCES JAPAN, INC.Inventors: Takefumi Gemba, Ryoichi Nagata
-
Patent number: 10149905Abstract: Summary Problem The purpose of the present invention is to provide: a chiral nucleic acid adjuvant having anti-tumor activity; and an anti-tumor agent. Solution The present invention relates to an adjuvant for anti-tumor agent, wherein the adjuvant comprises oligonucleotides which comprise two to four CpG motif each represented by 5?-X1CpGX2-3? and has a length of 14 to 32 nucleotides, wherein a nucleic acid at 3? end side of at least two CpG motifs is connected by phosphorothioate linkage, wherein each nucleic acid at 3? end and 5? end of the oligonucleotide is S type nucleic acid connected by phosphorothioate linkage, and wherein the oligonucleotide comprises at least one nucleic acid without phosphorothioate modification. The present invention relates to an anti-tumor agent containing its adjuvant.Type: GrantFiled: January 14, 2015Date of Patent: December 11, 2018Assignees: SHIN NIPPON BIOMEDICAL LABORATORIES, LTD., WAVE LIFE SCIENCES JAPAN, INC.Inventors: Takefumi Gemba, Ryoichi Nagata, Yusuke Torikai
-
Patent number: 10144933Abstract: Problem The purpose of the present invention is to provide: a chiral nucleic acid adjuvant having immunity-inducing activity and an immunity-inducing activator. Solution The present invention relates to an adjuvant which comprises oligonucleotides which comprise two to four sequences each represented by 5?-X1CpG X2-3? and has a length of 14 to 32 nucleotides, wherein a nucleic acid at 3? end side of at least two CpG motifs is connected by phosphorothioate linkage, wherein each nucleic acids at 3? end and 5? end of the oligonucleotide is S type nucleic acids connected by phosphorothioate linkage, and wherein the oligonucleotide comprises at least one nucleic acid without phosphorothioate modification. The present invention relates to an immunity-inducible activator comprising the adjuvant.Type: GrantFiled: January 14, 2015Date of Patent: December 4, 2018Assignees: SHIN NIPPON BIOMEDICAL LABORATORIES, LTD., WAVE LIFE SCIENCES JAPAN, INC.Inventors: Takefumi Gemba, Ryoichi Nagata, Ikumi Shiga
-
Patent number: 9695219Abstract: A novel polypeptide which has an excellent angiogenesis-inducing activity and an excellent antibacterial activity, and a novel angiogenesis-inducing agent which contains the polypeptide as an effective ingredient or a novel agent for treating a wound(s) which contains the polypeptide as an effective ingredient are disclosed. The polypeptide of the present invention is a polypeptide whose amino acid sequence is shown in any one of SEQ ID NOs:1 to 6, 8 and 10. The angiogenesis-inducing agent which contains the polypeptide of the present invention as an effective ingredient is useful for the prevention, amelioration or treatment of a disease such as a burns, decubitus, wound, skin ulcer, leg ulcer, diabetic ulcer, occlusive arterial disease and arteriosclerosis obliteran.Type: GrantFiled: January 23, 2015Date of Patent: July 4, 2017Assignee: FunPep Inc.Inventors: Takefumi Gemba, Hideki Tomioka, Nao Tamura, Ryoko Sata, Akito Maeda, Akiko Tenma, Toshihide Kanamori, Yoshimi Saito, Shintaro Komaba, Ryuichi Morishita
-
Patent number: 9617547Abstract: Problem The purpose of the present invention is to provide: a stereo isomer of a novel CpG oligonucleotide, which has excellent stability; and a CpG oligonucleotide which has a capability of producing interferon-? (IFN?). Solution The present invention relates to an oligonucleotide which contains two to four sequences each represented by the formula 5?-X1X2CpGX3X4-3? (formula (I)) and has a length of 14 to 32 nucleotides. In formula (I), CpG represents a non-methylated CpG residue having a phosphate skeleton modification, X1X2 represents any one of AA, AT, GA and GT, and X3X4 represents any one of TT, AT, AC and CG. The oligonucleotide has at least one phosphate skeleton modification at an S-form stereoisomer located at a site other than the CpG.Type: GrantFiled: July 12, 2013Date of Patent: April 11, 2017Assignees: Shin Nippon Biomedical Laboratories, Ltd., WAVE LIFE SCIENCES JAPANInventor: Takefumi Gemba
-
Publication number: 20160333349Abstract: Problem The purpose of the present invention is to provide: a chiral nucleic acid adjuvant having immunity-inducing activity and an immunity-inducing activator. Solution The present invention relates to an adjuvant which comprises oligonucleotides which comprise two to four sequences each represented by 5?-X1CpG X2-3? and has a length of 14 to 32 nucleotides, wherein a nucleic acid at 3? end side of at least two CpG motifs is connected by phosphorothioate linkage, wherein each nucleic acids at 3? end and 5? end of the oligonucleotide is S type nucleic acids connected by phosphorothioate linkage, and wherein the oligonucleotide comprises at least one nucleic acid without phosphorothioate modification. The present invention relates to an immunity-inducible activator comprising the adjuvant.Type: ApplicationFiled: January 14, 2015Publication date: November 17, 2016Inventors: Takefumi GEMBA, Ryoichi NAGATA, IKUMI Shiga
-
Publication number: 20160331835Abstract: An adjuvant which comprises oligonucleotides which comprise two to four CpG motifs each represented by 5?-X1CpGX2-3? and has a length of 14 to 32 nucleotides, wherein a nucleic acid at 3? end side of at least two CpG motifs is connected by phosphorothioate linkage, wherein each nucleic acids at 3? end and 5? end of the oligonucleotide is S type nucleic acids connected by phosphorothioate linkage, and wherein the oligonucleotide comprises at least one nucleic acid without phosphorothioate modification. The present invention relates to an adjuvant comprising the oligonucleotide represented by the sequence number 67. The present invention relates to an anti-allergic agent comprising these adjuvant.Type: ApplicationFiled: January 14, 2015Publication date: November 17, 2016Inventors: Takefumi Gemba, Ryoichi Nagata
-
Publication number: 20160331836Abstract: Summary Problem The purpose of the present invention is to provide: a chiral nucleic acid adjuvant having anti-tumor activity; and an anti-tumor agent. Solution The present invention relates to an adjuvant for anti-tumor agent, wherein the adjuvant comprises oligonucleotides which comprise two to four CpG motif each represented by 5?-X1CpGX2-3? and has a length of 14 to 32 nucleotides, wherein a nucleic acid at 3? end side of at least two CpG motifs is connected by phosphorothioate linkage, wherein each nucleic acid at 3? end and 5? end of the oligonucleotide is S type nucleic acid connected by phosphorothioate linkage, and wherein the oligonucleotide comprises at least one nucleic acid without phosphorothioate modification. The present invention relates to an anti-tumor agent containing its adjuvant.Type: ApplicationFiled: January 14, 2015Publication date: November 17, 2016Inventors: Takefumi Gemba, Ryoichi Nagata, Yusuke Ukai
-
Patent number: 9376470Abstract: Novel polypeptides which have an excellent angiogenesis-inducing activity and an excellent antibacterial activity and medical uses thereof are disclosed. The amino acid sequences of the novel polypeptides are shown in any one of SEQ ID NOs:1 to 6. These polypeptides have angiogenesis-inducing and antibacterial activities. Such polypeptides are useful for the prevention, amelioration or treatment of skin wounds caused by a cut wound, surgical wound, erosion, burn, decubitus, intractable wound, skin ulcer, leg ulcer, diabetic ulcer, occlusive arterial disease or arteriosclerosis obliteran, and for the prevention, amelioration or treatment of bacterial infection in such skin wounds, and the like.Type: GrantFiled: November 27, 2009Date of Patent: June 28, 2016Assignee: FunPep Inc.Inventors: Takefumi Gemba, Hideki Tomioka, Ryoko Sata, Nao Tamura, Akito Maeda, Toshihide Kanamori, Yoshimi Saito, Shintaro Komaba, Ryuichi Morishita
-
Publication number: 20150166999Abstract: Problem The purpose of the present invention is to provide: a stereo isomer of a novel CpG oligonucleotide, which has excellent stability; and a CpG oligonucleotide which has a capability of producing interferon-? (IFN?). Solution The present invention relates to an oligonucleotide which contains two to four sequences each represented by the formula 5?-X1X2CpGX3X4-3? (formula (I)) and has a length of 14 to 32 nucleotides. In formula (I), CpG represents a non-methylated CpG residue having a phosphate skeleton modification, X1X2 represents any one of AA, AT, GA and GT, and X3X4 represents any one of TT, AT, AC and CG. The oligonucleotide has at least one phosphate skeleton modification at an S-form stereoisomer located at a site other than the CpG.Type: ApplicationFiled: July 12, 2013Publication date: June 18, 2015Applicant: Shin Nippon Biomedical Laboratories, Ltd.Inventor: Takefumi Gemba
-
Publication number: 20150133365Abstract: A novel polypeptide which has an excellent angiogenesis-inducing activity and an excellent antibacterial activity, and a novel angiogenesis-inducing agent which contains the polypeptide as an effective ingredient or a novel agent for treating a wound(s) which contains the polypeptide as an effective ingredient are disclosed. The polypeptide of the present invention is a polypeptide whose amino acid sequence is shown in any one of SEQ ID NOs:1 to 6, 8 and 10. The angiogenesis-inducing agent which contains the polypeptide of the present invention as an effective ingredient is useful for the prevention, amelioration or treatment of a disease such as a burns, decubitus, wound, skin ulcer, leg ulcer, diabetic ulcer, occlusive arterial disease and arteriosclerosis obliteran.Type: ApplicationFiled: January 23, 2015Publication date: May 14, 2015Applicant: ANGES MG, INC.Inventors: Takefumi Gemba, Hideki Tomioka, Nao Tamura, Ryoko Sata, Akito Maeda, Akiko Tenma, Toshihide Kanamori, Yoshimi Saito, Shintaro Komaba, Ryuichi Morishita
-
Patent number: 8969311Abstract: A novel polypeptide which has an excellent angiogenesis-inducing activity and an excellent antibacterial activity, and a novel angiogenesis-inducing agent which contains the polypeptide as an effective ingredient or a novel agent for treating a wound(s) which contains the polypeptide as an effective ingredient are disclosed. The polypeptide of the present invention is a polypeptide whose amino acid sequence is shown in any one of SEQ ID NOs:1 to 6, 8 and 10. The angiogenesis-inducing agent which contains the polypeptide of the present invention as an effective ingredient is useful for the prevention, amelioration or treatment of a disease such as a burns, decubitus, wound, skin ulcer, leg ulcer, diabetic ulcer, occlusive arterial disease and arteriosclerosis obliteran.Type: GrantFiled: May 25, 2010Date of Patent: March 3, 2015Assignee: AnGes MG, Inc.Inventors: Takefumi Gemba, Hideki Tomioka, Nao Tamura, Ryoko Sata, Akito Maeda, Akiko Tenma, Toshihide Kanamori, Yoshimi Saito, Shintaro Komaba, Ryuichi Morishita
-
Patent number: 8470765Abstract: A novel polypeptide, and an antibacterial agent, antifungal agent and/or antiseptic containing as an effective ingredient the polypeptide are disclosed. The polypeptide of this invention has an amino acid sequence shown in SEQ ID NOs:1 to 12 and 13 to 31. This antibacterial agent, antifungal agent and/or antiseptic is useful for the prevention, amelioration or treatment of diseases such as burn, decubitus, wound, skin ulcer, leg ulcer, diabetic ulcer, occlusive arterial disease and arteriosclerosis obliterans, cellulitis, acute lymphangitis, lymphadenitis, erysipelas, skin abscess, necrotizing subcutaneous infection, staphylococcal scalded skin syndrome (SSSS), folliculitis, facial furuncle, suppurative hidradenitis, carbuncle, infectious paronychia, erythrasma and severe infection (sepsis).Type: GrantFiled: March 5, 2010Date of Patent: June 25, 2013Assignee: AnGes MG, Inc.Inventors: Takefumi Gemba, Hideki Tomioka, Nao Tamura, Akiko Tenma
-
Publication number: 20120172287Abstract: A novel polypeptide which has an excellent angiogenesis-inducing activity and an excellent antibacterial activity, and a novel angiogenesis-inducing agent which contains the polypeptide as an effective ingredient or a novel agent for treating a wound(s) which contains the polypeptide as an effective ingredient are disclosed. The polypeptide of the present invention is a polypeptide whose amino acid sequence is shown in any one of SEQ ID NOs:1 to 6, 8 and 10. The angiogenesis-inducing agent which contains the polypeptide of the present invention as an effective ingredient is useful for the prevention, amelioration or treatment of a disease such as a burns, decubitus, wound, skin ulcer, leg ulcer, diabetic ulcer, occlusive arterial disease and arteriosclerosis obliteran.Type: ApplicationFiled: May 25, 2010Publication date: July 5, 2012Applicant: ANGES MG, Inc.Inventors: Takefumi Gemba, Hideki Tomioka, Nao Tamura, Ryoko Sata, Akito Maeda, Akiko Tenma, Toshihide Kanamori, Yoshimi Saito, Shintaro Komaba, Ryuichi Morishita
-
Publication number: 20120122766Abstract: Novel polypeptides which have an excellent angiogenesis-inducing activity and an excellent antibacterial activity and medical uses thereof are disclosed. The amino acid sequences of the novel polypeptides are shown in any one of SEQ ID NOs:1 to 6. These polypeptides have angiogenesis-inducing and antibacterial activities. Such polypeptides are useful for the prevention, amelioration or treatment of skin wounds caused by a cut wound, surgical wound, erosion, burn, decubitus, intractable wound, skin ulcer, leg ulcer, diabetic ulcer, occlusive arterial disease or arteriosclerosis obliteran, and for the prevention, amelioration or treatment of bacterial infection in such skin wounds, and the like.Type: ApplicationFiled: November 27, 2009Publication date: May 17, 2012Applicant: ANGES MG, Inc.Inventors: Takefumi Gemba, Hideki Tomioka, Ryoko Sata, Nao Tamura, Akito Maeda, Toshihide Kanamori, Yoshimi Saito, Shintaro Komaba, Ryuichi Morishita
-
Publication number: 20120052104Abstract: A novel polypeptide, and an antibacterial agent, antifungal agent and/or antiseptic containing as an effective ingredient the polypeptide are disclosed. The polypeptide of this invention has an amino acid sequence shown in SEQ ID NOs:1 to 12 and 13 to 31. This antibacterial agent, antifungal agent and/or antiseptic is useful for the prevention, amelioration or treatment of diseases such as burn, decubitus, wound, skin ulcer, leg ulcer, diabetic ulcer, occlusive arterial disease and arteriosclerosis obliterans, cellulitis, acute lymphangitis, lymphadenitis, erysipelas, skin abscess, necrotizing subcutaneous infection, staphylococcal scalded skin syndrome (SSSS), folliculitis, facial furuncle, suppurative hidradenitis, carbuncle, infectious paronychia, erythrasma and severe infection (sepsis).Type: ApplicationFiled: March 5, 2010Publication date: March 1, 2012Applicant: ANGES MG, Inc.Inventors: Takefumi Gemba, Hideki Tomioka, Nao Tamura, Akiko Tenma
-
Methods and compositions for treating, inhibiting and reversing disorders of the intervertebral disc
Patent number: 7585848Abstract: Described herein are methods and compositions for inhibiting, treating and reversing intervertebral disc disorders using transcription factor inhibitors. In certain embodiments, the transcription factor inhibitor targets the transcription factor NF-?B. Also described are methods and compositions where intervertebral disc disorder is reversed using a decoy oligodeoxy-nucleotide that blocks NF-?B.Type: GrantFiled: January 11, 2005Date of Patent: September 8, 2009Assignees: Rush University Medical Center, Anges MG, Inc.Inventors: Koichi Masuda, Takefumi Gemba -
Publication number: 20090215868Abstract: The present invention provides a prophylactic, therapeutic or ameliorative medicament for chronic obstructive pulmonary disease (COPD), cystic fibrosis or pulmonary hypertension. More specifically, the present invention provides: (1) a prophylactic, therapeutic or ameliorative medicament for chronic obstructive pulmonary disorder (COPD), cystic fibrosis or pulmonary hypertension, having an NF-?B decoy as the active ingredient thereof; (2) the NF-?B decoy is an oligonucleotide containing the binding sequence GGGRHTYYC (where R represents either A or G; Y represents either C or T; and H represents either A, C or T); (3) an oligonucleotide wherein the NF-?B binding sequence is GGGATTTCCC or GGGACTTTCC; (4) an oligonucleotide wherein the NF-?B decoy is represented by SEQ ID NO:3; (5) the NF-?B decoy is a double-stranded oligonucleotide; (6) the NF-?B decoy is administered in the form of a fine powder; and (7) the NF-?B decoy fine powder is a dry powder.Type: ApplicationFiled: January 12, 2006Publication date: August 27, 2009Applicant: ANGES MG, INC.Inventors: Kunimiki Otsu, Tetsu Saito, Takefumi Gemba
-
Publication number: 20090143319Abstract: Double-stranded oligonucleotides useful as decoy oligonucleotides having a high binding ability to a transcription factor and having a reduced cytotoxicity are disclosed. Each of the double-stranded oligonucleotides is formed by hybridization of a sense strand oligonucleotide of the following Formula A: 5?-N(m)-G-Consensus Sequence-C—N(n)-3???(Formula A) (wherein N(m) is a flanking sequence at the 5?-end, and represents that “N” (s) in the number of m is(are) ligated; N(n) is a flanking sequence at the 3?-end, and represents that “N” (s) in the number of m is(are) ligated; all “N” (s) each independently represent(s) nucleotide A, G, T, C or U; m and n represent each independently an integer of 0 to 20; and Consensus Sequence represents a consensus sequence to which a transcription factor binds) and an antisense strand oligonucleotide complementary to said sense strand oligonucleotide.Type: ApplicationFiled: June 6, 2006Publication date: June 4, 2009Applicant: AnGesMG, Inc.Inventors: Takefumi Gemba, Nobuhiro Ueno
-
Publication number: 20050227994Abstract: It is provided that a pharmaceutical composition inhibiting cartilage extracellular matrix degradation containing a compound of the formula (I): wherein R1 is hydroxy and the like; R2 is optionally substituted lower alkyl and the like; R3 is hydrogen atom and the like; R4 is optionally substituted arylene and the like; R5 is a bond, or —C?C— and the like; R6 is optionally substituted aryl and the like, its optically active substance, its prodrug, their pharmaceutically acceptable salt, or solvate thereof.Type: ApplicationFiled: March 26, 2003Publication date: October 13, 2005Inventors: Takefumi Gemba, Hiroyuki Okamoto, Fumihiko Watanabe